Molecular Interaction Characterization Strategies for the Development of New Biotherapeutic Antibody Modalities

por Wang, Xiangdan, Phan, Minh Michael, Li, Ji, Gill, Herman, Williams, Simon, Gupta, Nidhi, Quarmby, Valerie, Yang, Jihong
Publicado 2020

Evaluation of a 3-hydroxypyridin-2-one (2,3-HOPO) Based Macrocyclic Chelator for (89)Zr(4+) and Its Use for ImmunoPET Imaging of HER2 Positive Model of Ovarian Carcinoma in Mice

por N.Tinianow, Jeff, Pandya, Darpan N., Pailloux, Sylvie L., Ogasawara, Annie, Vanderbilt, Alexander N., Gill, Herman S., Williams, Simon-P., Wadas, Thaddeus J., Magda, Darren, Marik, Jan
Publicado 2016

VCAM-1 Density and Tumor Perfusion Predict T-cell Infiltration and Treatment Response in Preclinical Models()()

por Riegler, Johannes, Gill, Herman, Ogasawara, Annie, Hedehus, Maj, Javinal, Vincent, Oeh, Jason, Ferl, Gregory Z., Marik, Jan, Williams, Simon, Sampath, Deepak, Schartner, Jill, Carano, Richard A.D.
Publicado 2019

Head-to-head comparison of DFO* and DFO chelators: selection of the best candidate for clinical (89)Zr-immuno-PET

por Chomet, Marion, Schreurs, Maxime, Bolijn, Maria J., Verlaan, Mariska, Beaino, Wissam, Brown, Kari, Poot, Alex J., Windhorst, Albert D., Gill, Herman, Marik, Jan, Williams, Simon, Cowell, Joseph, Gasser, Gilles, Mindt, Thomas L., van Dongen, Guus A. M. S, Vugts, Danielle J.
Publicado 2020

ImmunoPET helps predicting the efficacy of antibody-drug conjugates targeting TENB2 and STEAP1

por Williams, Simon-Peter, Ogasawara, Annie, Tinianow, Jeff N., Flores, Judith E., Kan, David, Lau, Jeffrey, Go, MaryAnn, Vanderbilt, Alexander N., Gill, Herman S., Miao, Li, Goldsmith, Joshua, Rubinfeld, Bonnee, Mao, Weiguang, Firestein, Ron, Yu, Shang-Fan, Marik, Jan, Terwisscha van Scheltinga, Anton G.T.
Publicado 2016